Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 32

  • 956 clinical trials
  • 393 recruiting
  • 345 conditions
  • 28 countries

Conditions in this area

345 conditions with trials, the busiest first

Breast cancer168Prostate cancer101Ovarian cancer91Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer41Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer18Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+321

Clinical trials in Reproductive system and breast disorders

956 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

956 clinical trials

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Early Detection and Treatment of ER Positive HER2 Negative Breast Cancer Using Palbociclib, Fulvestrant, and Drug Combination for Patients with Molecular Relapse

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:The Royal Marsden NHS Foundation Trust

Triple negative breast cancer

Recruiting

Study on Imatinib for Patients with Triple Negative Breast Cancer to Convert it to ER-Positive Breast Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Vaestra Goetalandsregionen

Breast cancer

Recruiting

Study on Post-Neoadjuvant Therapy for Early Breast Cancer Using Ipatasertib, Inavolisib, and Atezolizumab for Patients with High-Risk Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Infertility female

Recruiting

Study on Random Start Ovarian Stimulation with Follitropin Alfa, Dydrogesterone, and Triptorelin Acetate for Women Undergoing Elective Oocyte Cryopreservation to Prevent Infertility

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Dydrogesterone
  • Sponsor:UZ Brussel

Endometrial cancer+38

Recruiting

Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ds-3939A
  • Sponsor:Daiichi Sankyo Inc.

Intraductal proliferative breast lesion

Recruiting

Evaluation of Contrast-Enhanced Spectral Mammography Using Iopromide in Women with Suspicious Breast Lesions to Improve Diagnostic Accuracy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iopromide
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Breast cancer

Recruiting

Study on Indocyanine Green in Axillary Lymph Nodes for Patients with Breast Cancer and Metastatic Lymph Nodes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Indocyanine Green
  • Sponsor:Centro Di Riferimento Oncologico Di Aviano

Breast cancer metastatic

Recruiting

Study Comparing FDG-PET/CT and CT for Monitoring Treatment Response in Patients with Metastatic Breast Cancer Using Fludeoxyglucose (18F)

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Fludeoxyglucose (18F)
  • Sponsor:Odense University Hospital

Prostate cancer+1

Recruiting

Study on Atorvastatin's Effect on Prostate Cancer Progression in Patients Undergoing Androgen Deprivation Therapy

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Pirkanmaan hyvinvointialue

Endometrial cancer+2

Recruiting

Study on Dostarlimab and Niraparib for Patients with Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Arcagy Gineco

Breast cancer metastatic

Recruiting

Study on the Effectiveness of Durvalumab for Patients with Metastatic Breast Cancer in Early Chemotherapy Stages

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Unicancer

HER2 positive breast cancer

Recruiting

Study on Reducing Treatment for Patients with HER2-Positive Metastatic Breast Cancer Using Trastuzumab and Drug Combination After 2 Years of Controlled Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Unicancer

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab77 clinical trialsLetrozole73 clinical trialsFulvestrant58 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane46 clinical trialsAnastrozole44 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.